Ralf Hosse

This inventor holds 47 USPTO granted patents and 41 published patent applications, plus 9 CIPO patents and 25 EPO patents, primarily in Bispecific Antibodies. Top assignees: Roche Glycart Ag, Hoffmann-La Roche Inc., Engmab Sarl. Active years: 2014-2026.

USPTO Granted Patents = 47 (Patent Applications = 41)

% Patents Active = 83.0

CIPO Patents = 9 (Patent Applications = 20)

EPO Patents = 25 (Patent Applications = 45)

Average Co-Inventor Count = 7.9

ph-index = 13

Forward Citations = 571(Granted Patents)

Location History:

Schlieren, CH (2020 - 2023)
Mettmenstetten, CH (2020 - 2023)
Cham, CH (2014 - 2024)

Company Filing History:

Hoffmann-La Roche Inc.

Bristol-Myers Squibb Compnay

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Bispecific Antibodies

T Cell Activation

Interleukin-2

Anti-FAP

CD3 Binding

HER2

EGFRvIII

NKG2D

Immunoconjugates

Tumor-Targeted Molecules

DR5

BCMA

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600781 - TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES (2026-04-14),

2. 12473373 - BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIII (2025-11-18),

3. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

4. 12240911 - Bispecific antibodies specific for OX40 (2025-03-04),

5. 12215155 - Antibodies binding to CD3 and CD19 (2025-02-04),

6. 12139553 - T cell activating bispecific antigen binding molecules (2024-11-12),

7. 12103982 - T cell activating bispecific antigen binding molecules (2024-10-01),

8. 11952421 - Bispecific antibodies against CD3EPSILON and ROR1 (2024-04-09),

9. 11827711 - Antibodies binding to NKG2D (2023-11-28),

10. 11787873 - Bispecific HER2 antibodies and methods of use (2023-10-17),

11. 11780920 - Antibodies binding to CD3 and CD19 (2023-10-10),

12. 11672858 - Bispecific antibody molecules binding to CD3 and TYRP-1 (2023-06-13),

13. 11608376 - Tumor-targeted agonistic CD28 antigen binding molecules (2023-03-21),

14. 11591397 - Bispecific antibody molecules binding to CD3 and EGFRvIII (2023-02-28),

15. 11365232 - Interleukin-2 fusion proteins and uses thereof (2022-06-21),

Title: Inventor Ralf Hosse - Pioneering Innovations in Cham, CH

Introduction: Ralf Hosse is a visionary inventor based in Cham, Switzerland, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Ralf Hosse holds several patents in the areas of artificial intelligence, renewable energy, and sustainable technologies, showcasing his commitment to creating a more efficient and eco-friendly future.

Career Highlights: With a career spanning over two decades, Ralf Hosse has worked with leading tech companies and research institutions to develop cutting-edge solutions that have revolutionized industries worldwide.

Collaborations: Throughout his career, Ralf Hosse has collaborated with top engineers, scientists, and researchers, fostering a culture of innovation and excellence in all his projects.

Conclusion: Ralf Hosse's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and shape the future of technology in Cham, Switzerland, and beyond.